Athersys goes public, raises $65M in VC

Athersys has completed a reverse merger, taking the company public as it raised $65 million in new venture backing. Radius Ventures led the financing, with significant participation from OrbiMed Advisors, RA Capital Management, Accipiter Capital Management, Hambrecht & Quist Capital Management, MPM BioEquities, and Pappas Ventures. Much of that money goes to the development of ATHX-105 and its stem cell product--MultiStem--to treat patients for certain cardiovascular disorders.

"We are excited to invest in Athersys in connection with its debut as a publicly-traded company," said Jordan Davis, managing partner of Radius. "In particular, we are attracted to Athersys' "fast follower" approach and its focus on developing products that have "best-in-class" potential in multibillion-dollar markets."

- check out this press release for more
- read the report from dBusiness 

ALSO: Aquinox Pharmaceuticals has completed a $14.5 million Series A round of venture capital financing. Ventures West Capital led the financing. Release

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.